Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab + lenvatinib in selected advanced solid tumors
CTR20211874Phase 2Completed
- Sponsor
- BeiGene
- Start
- Aug 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tislelizumab, lenvatinib in non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), transitional cell carcinoma (TCC), renal cell carcinoma (RCC), gastric cancer (GC), sponsored by BeiGene. Started Aug 2021; status: completed.
02
Drugs
tislelizumablenvatinib
03
Conditions
non-small cell lung cancer (NSCLC)head and neck squamous cell carcinoma (HNSCC)transitional cell carcinoma (TCC)renal cell carcinoma (RCC)gastric cancer (GC)
Beyond the preview
Go deeper on CTR20211874.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20211874.